Connection

SUSAN HILSENBECK to Time Factors

This is a "connection" page, showing publications SUSAN HILSENBECK has written about Time Factors.
Connection Strength

0.219
  1. Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat. 2005 Jan; 89(2):173-8.
    View in: PubMed
    Score: 0.029
  2. Mouse-INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy. J Pathol. 2022 02; 256(2):186-201.
    View in: PubMed
    Score: 0.023
  3. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat. 1998; 52(1-3):227-37.
    View in: PubMed
    Score: 0.018
  4. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
    View in: PubMed
    Score: 0.015
  5. Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis. Proc Natl Acad Sci U S A. 2014 Jan 21; 111(3):1008-13.
    View in: PubMed
    Score: 0.013
  6. Selective small molecule Stat3 inhibitor reduces breast cancer tumor-initiating cells and improves recurrence free survival in a human-xenograft model. PLoS One. 2012; 7(8):e30207.
    View in: PubMed
    Score: 0.012
  7. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
    View in: PubMed
    Score: 0.011
  8. Drain data to predict clinically relevant pancreatic fistula. HPB (Oxford). 2010 Sep; 12(7):472-81.
    View in: PubMed
    Score: 0.011
  9. Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat. 2010 Oct; 123(3):651-60.
    View in: PubMed
    Score: 0.010
  10. Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells. 2008 Dec; 26(12):3205-9.
    View in: PubMed
    Score: 0.009
  11. Early termination of a phase II clinical trial. Control Clin Trials. 1988 Sep; 9(3):177-88.
    View in: PubMed
    Score: 0.009
  12. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008 Sep 01; 26(25):4078-85.
    View in: PubMed
    Score: 0.009
  13. Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature. Cancer. 1988 Jun 01; 61(11):2161-7.
    View in: PubMed
    Score: 0.009
  14. The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res. 2007 Oct 15; 13(20):6224-31.
    View in: PubMed
    Score: 0.009
  15. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
    View in: PubMed
    Score: 0.007
  16. Medical complications and outcomes after hip fracture repair. Arch Intern Med. 2002 Oct 14; 162(18):2053-7.
    View in: PubMed
    Score: 0.006
  17. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069. Cancer Epidemiol Biomarkers Prev. 2002 May; 11(5):467-74.
    View in: PubMed
    Score: 0.006
  18. Immunofluorescence microscopy and flow cytometry characterization of chemical induction of latent Epstein-Barr virus. Clin Diagn Lab Immunol. 1998 Jan; 5(1):91-7.
    View in: PubMed
    Score: 0.004
  19. Optimal mastectomy timing. J Natl Cancer Inst. 1992 Mar 04; 84(5):346-8.
    View in: PubMed
    Score: 0.003
  20. A demonstration that breast cancer recurrence can be predicted by neural network analysis. Breast Cancer Res Treat. 1992; 21(1):47-53.
    View in: PubMed
    Score: 0.003
  21. Lung carcinoma in 1,336 patients. Am J Clin Oncol. 1991 Dec; 14(6):496-508.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.